I-Corps: Nanotechnology for Boosting Vaccine Efficacy and Longevity

I-Corps：提高疫苗功效和寿命的纳米技术

• 批准号: 1742660
• 负责人: Julie Champion
• 金额: $ 5万
• 依托单位: Georgia Tech Research Corporation
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-06-15 至 2018-05-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1742660&HistoricalAwards=false
• 关键词: Corps; Nanotechnology; Boosting; Vaccine; Efficacy

The broader impact/commercial potential of this I-Corps project lies primarily in the enhancement of vaccine safety and efficacy. The project could potentially accelerate the development of safer and more cost-effective vaccines, and help transcend the current "safety-vs-efficacy" paradigm of current vaccine additive research. Given the escalating interest in immunomodulatory biologics from pharmaceutical companies, it is anticipated that these antibodies could enter the market at an opportune time from both regulatory and process development perspectives. Additionally, as the role of antibodies is becoming more fully elucidated in the field of immune-engineering, this antibody coating technology could also enhance treatments for cancer and autoimmune diseases.This I-Corps project aims to explore the use of host (human) derived proteins as safe vaccine additives. Antibodies coat pathogens during the body's immune response to an infection, and these proteins may be able to enhance the immunogenicity of nanoparticulate or inactivated pathogen vaccines. Antibodies immobilized on the particles' surface would remain bound. Any non-immobilized, soluble antibody in the formulation should be recognized as host protein and consequently non-immunogenic, eliminating any off-target inflammatory effects such as those caused by soluble pathogen-derived vaccine additives.

I-Corps项目的更广泛影响/商业潜力主要在于提高疫苗的安全性和效力。该项目有可能加速开发更安全、更具成本效益的疫苗，并有助于超越目前疫苗添加剂研究的“安全性vs有效性”范式。鉴于制药公司对免疫调节生物制剂的兴趣不断升级，从监管和工艺开发的角度来看，预计这些抗体可以在适当的时候进入市场。此外，随着抗体在免疫工程领域的作用越来越被充分阐明，这种抗体包被技术也可以增强对癌症和自身免疫性疾病的治疗。I-Corps项目旨在探索使用宿主（人类）衍生蛋白作为安全的疫苗添加剂。在机体对感染的免疫反应中，抗体包裹在病原体表面，这些蛋白质可能能够增强纳米颗粒或灭活病原体疫苗的免疫原性。固定在颗粒表面的抗体将保持结合状态。制剂中任何非固定化的可溶性抗体都应被识别为宿主蛋白，因此是非免疫原性的，从而消除任何脱靶炎症效应，例如由可溶性病原体衍生疫苗添加剂引起的炎症效应。